Revelation Biosciences is a clinical-stage life sciences company focused on immunologic-based therapies and diagnostics. Its lead therapeutic candidate, REVTx-99, is an intranasal immunomodulator in development for early treatment of SARS-CoV-2 and other respiratory viral infections and acts by stimulating the innate immune system via TLR4 to induce protective cytokines including interferons. The company is also developing REVTx-200, an intranasal immunomodulator intended as an adjunct to intramuscular vaccination, and REVDx-501, a rapid lateral-flow point-of-care diagnostic that provides visual results in under 10 minutes. Revelation plans to expand REVTx-99 indications to include influenza A and B, parainfluenza, and respiratory syncytial virus. The company is in the clinical stage and intends to use recent financing to advance development programs and support general and administrative operations. The press release notes regulatory and operational risks typical for development-stage life sciences companies.

Total raised

$4M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2021